| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2019-04-17 |
复牌提示：
2019-04-17 09:09:54 停牌，复牌日期 2019-04-18 00:00:01
|
| 2019-04-17 |
详情>>
内部人交易：
Danilkovitch Alla等共交易3笔
|
| 2019-03-15 |
详情>>
股本变动：
变动后总股本3452.66万股
变动原因 ▼▲
- 原因：
- From December 31,2017 to December 31,2018
Stock issued upon exercise of stock options, net of shares acquired
|
| 2019-03-15 |
详情>>
业绩披露：
2018年年报每股收益1.07美元,归母净利润3690.10万美元,同比去年增长320.05%
|
| 2018-11-07 |
详情>>
业绩披露：
2018年三季报(累计)每股收益0.13美元,归母净利润437.10万美元,同比去年增长-36.46%
|
| 2018-08-08 |
详情>>
业绩披露：
2018年中报每股收益0.00美元,归母净利润16.40万美元,同比去年增长118.66%
|
| 2018-05-11 |
股东大会：
将于2018-06-26召开股东大会
会议内容 ▼▲
- 1.Approve amendments to our articles of incorporation, as amended and supplemented, to: (i) permit the removal of directors without cause and (ii) decrease the number of authorized shares;
2.Approve the amendment and restatement of our bylaws, including amendments to:
(i)remove the requirement that our annual meetings of stockholders be held within six months of fiscal year-end,
(ii)require majority voting in uncontested elections of directors,
(iii)amend our advance notice provisions for director nominations and stockholder proposals,
(iv)require stockholder ratification of director compensation,
(v)extend the timeframe for which our Board of Directors may fix a record date from 60 days to 90 days,
(vi)implement permissive, rather than mandatory, provisions related to the advancement of expenses of executive officers in certain legal proceedings, and
(vii)delete sections of the bylaws that are unnecessary or no longer applicable and make immaterial revisions consistent with Maryland corporate law.
3.Elect each director nominee named in the proxy statement to serve until the 2019 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified;
4.Consider and vote to approve, on a non-binding, advisory basis, the executive compensation paid by us;
5.Recommend, on a non-binding, advisory basis, the frequency of the advisory vote related to the executive compensation paid by us;
6.Ratify the compensation of our directors;
7.Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
8.Approve the Osiris Therapeutics, Inc. 2018 Long-Term Incentive Plan;
9.Transact such other matters as may properly come before the 2018 Annual Meeting, or any adjournments or postponements thereof.
|
| 2018-05-10 |
详情>>
业绩披露：
2018年一季报每股收益-0.07美元,归母净利润-232万美元,同比去年增长-41.72%
|
| 2018-03-28 |
详情>>
业绩披露：
2017年年报每股收益0.25美元,归母净利润878.50万美元,同比去年增长334.33%
|
| 2018-03-28 |
详情>>
业绩披露：
2016年年报每股收益-0.11美元,归母净利润-374.9万美元,同比去年增长89.51%
|
| 2018-03-28 |
详情>>
业绩披露：
2015年年报每股收益-1.04美元,归母净利润-3575.4万美元,同比去年增长-1898.55%
|
| 2015-11-16 |
详情>>
业绩披露：
2015年三季报(累计)每股收益0.02美元,归母净利润62.20万美元,同比去年增长123.88%
|
| 2015-09-17 |
除权日：
美东时间 2015-10-14 每股派息0.20美元
|
| 2015-08-10 |
详情>>
业绩披露：
2015年中报每股收益0.07美元,归母净利润254.10万美元,同比去年增长178.18%
|
| 2015-05-11 |
详情>>
业绩披露：
2015年一季报每股收益0.04美元,归母净利润137.70万美元,同比去年增长200.88%
|
| 2015-04-30 |
股东大会：
将于2015-06-10召开股东大会
会议内容 ▼▲
- 1. The approval of an amendment to our articles of incorporation, as amended and supplemented (our "Charter"), to declassify the Board of Directors and adopt concurrent annual terms for all the members of the Board of Directors;
2. If Proposal 1 is approved, the election of five directors to serve until the annual meeting of stockholders in the year 2016 and until their respective successors are duly elected and qualified; or if Proposal 1 is not approved, the election of one director to serve until the annual meeting of stockholders in the year 2018 and until his successor is duly elected and qualified;
3. The ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015; 4. Such other matters as may properly come before the Annual Meeting, or any adjournments or postponements thereof.
|
| 2015-03-20 |
详情>>
业绩披露：
2014年年报每股收益-0.05美元,归母净利润-178.9万美元,同比去年增长-104.3%
|
| 2015-03-20 |
详情>>
业绩披露：
2013年年报每股收益1.25美元,归母净利润4163.80万美元,同比去年增长476.30%
|
| 2014-03-28 |
股东大会：
将于2014-05-06召开股东大会
会议内容 ▼▲
- 1. The election of two directors, each for a term of three years and until their respective successors are duly elected and qualified;
2. The approval of an amendment to our Amended and Restated 2006 Omnibus Plan to increase the aggregate number of shares of common stock that may be issued at any time pursuant to awards granted thereunder from 2,250,000 to 3,000,000, and to extend the termination date, after which awards may no longer be granted thereunder, from June 11, 2022 to May 6, 2024, and re-approval of the Amended and Restated 2006 Omnibus Plan, including for purposes of Section 162(m) of the Internal Revenue Code;
3. The ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014;
4. The approval, on a non-binding advisory basis, of the compensation paid to our named executive officers, as disclosed in this Proxy Statement;
5. Such other matters as may properly come before the Annual Meeting, or any adjournments or postponements thereof.
|
| 2013-04-09 |
股东大会：
将于2013-05-30召开股东大会
会议内容 ▼▲
- 1. The election of two directors, each for a term of three years and until their respective successors are duly elected and qualified;
2. The ratification of the appointment of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2013;
3. Such other matters as may properly come before the Annual Meeting, or any adjournments or postponements thereof.
|